25 Jan Polaris Clinical Development Program
Posted at 20:52h in Clinical Trial
The POLARIS clinical development program is being conducted by NLS Pharmaceutics. The investigational study drug, Mazindol ER, is a special extended-release (ER) formulation of mazindol and is being tested in this program to evaluate how well it works when given to adult subjects with narcolepsy with or without cataplexy. Additionally, the program is being conducted to determine the drug’s safety, tolerability, and how it is absorbed and processed in the body. A benefit of taking part in this clinical development program is that you and other people with narcolepsy may benefit from the outcome of the POLARIS studies.
Click here to learn more about the program. Click here to view recently announced interim clinical data.